@sgrosche.bsky.social
Our new preprint on DUSP4 in cancer is out. In vivo ARTi studies show DUSP4 loss doesn’t cause tumor regression and triggers fast compensatory reactivation. These results challenge DUSP4 as a monotherapy target. Link to preprint: www.biorxiv.org/content/10.6...
DUSP4 knockdown in BRAF V600E mutant colorectal cancer induces cell cycle arrest and halts tumor growth
Oncogenic signaling in cancer cells is essential for proliferation, and its disruption, either through inhibition or overactivation, can provide therapeutic opportunities. Dual specificity phosphatase 4 (DUSP4), a negative regulator of the MAPK pathway that dephosphorylates ERK, has been proposed as a potential target; however, its therapeutic relevance has not been evaluated in vivo. In this study, we show that DUSP4 knock-down induces G1 cell cycle arrest and reduces proliferation in BRAFV600E-mutant and BRAF inhibitor-resistant colorectal cancer models, both in vitro and in vivo, and induces a rapid DUSP5-mediated adaptive response. While treatment achieved tumor stasis indicating disease control, it did not yield tumor regression, suggesting that DUSP4 may have limited efficacy as a monotherapy target in cancer. ### Competing Interest Statement All authors are full time employees at Boehringer Ingelheim RCV.
www.biorxiv.org
January 16, 2026 at 1:08 PM
Our new preprint on DUSP4 in cancer is out. In vivo ARTi studies show DUSP4 loss doesn’t cause tumor regression and triggers fast compensatory reactivation. These results challenge DUSP4 as a monotherapy target. Link to preprint: www.biorxiv.org/content/10.6...
Reposted
The @fda.gov granted accelerated approval to the HER2 inhibitor zongertinib for certain adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors harbored mutations in the tyrosine kinase domain of HER2: buff.ly/Fq0u3yt
FDA grants accelerated approval to zongertinib for non-squamous NSCLC
On August 8, 2025, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinas
www.fda.gov
August 8, 2025 at 6:50 PM
The @fda.gov granted accelerated approval to the HER2 inhibitor zongertinib for certain adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors harbored mutations in the tyrosine kinase domain of HER2: buff.ly/Fq0u3yt
Reposted
"There’s really only one advice: work as hard as you can. [...] If more of us are trying, more of us are succeeding, and others are being carried through", says @apombo1.bsky.social Pombo, group leader at the #mdcBerlin | #mdcBIMSB.
👇 Watch the video and share to inspire others!
👇 Watch the video and share to inspire others!
Celebrating our #WomenInSTEM: Ana Pombo
YouTube video by Max Delbrück Center
youtu.be
February 17, 2025 at 8:31 AM
"There’s really only one advice: work as hard as you can. [...] If more of us are trying, more of us are succeeding, and others are being carried through", says @apombo1.bsky.social Pombo, group leader at the #mdcBerlin | #mdcBIMSB.
👇 Watch the video and share to inspire others!
👇 Watch the video and share to inspire others!
Reposted
Reposted
Are you a student with an interest in translational #cancer research? The lab of our Johannes Zuber (@johanneszuber.bsky.social) is recruiting a #masters student: www.imp.ac.at/career/open-...
#oncology, #cancerresearch, #masters
#oncology, #cancerresearch, #masters
Ref2501: Master thesis in Translational Cancer Research (Zuber lab) | Research Institute of Molecular Pathology
www.imp.ac.at
January 7, 2025 at 4:28 PM
Are you a student with an interest in translational #cancer research? The lab of our Johannes Zuber (@johanneszuber.bsky.social) is recruiting a #masters student: www.imp.ac.at/career/open-...
#oncology, #cancerresearch, #masters
#oncology, #cancerresearch, #masters